Study | Pre-test probabilitya (n) | Sensitivity% (95% CI) | Specificity% (95% CI) | LR+ (95% CI) | LR− (95% CI) | Post-test probability for study population: positive test (%) | Post-test probability for study population: negative test (%) |
---|---|---|---|---|---|---|---|
Transvaginal Ultrasound | |||||||
Abrao [10] | 52% (54/104) | 98 (95,100) | 100 (100,100) | ∞ | 0.02 (0.00, 0.1) | >99 | 2 |
Menada [17] TVS | 83% (75/90) | 56.5 | 92.5 | 7.57 | 0.47 | 97 | 60 |
Menada [17] RWC-TVSb,c | 83% (75/90) | 95.7 | 100.0 | ∞ | 0.04 | >99 | 15 |
Guerriero [15] | 44% (39/88) | 67 (55,73) | 92 (84, 100) | 8.2 (3.1,21.4) | 0.4 (0.2,0.6) | 87 | 22 |
Bazot [11] | 67% (54/81) | 93 (86,100) | 100 (100,100) | ∞ | 0.07 (0.03,0.2) | >99 | 12 |
Hudelist [16] | 24% (48/200) | 96 (90,100) | 98 (96, 100) | 48.6 (15.8,149.1) | 0.04 (0.01,0.2) | 94 | 1 |
Piketty [18] | 56% (75/134) | 91 (84,97) | 97 (92,100) | 26.3 (6.7, 102.8) | 0.1 (0.05, 0.2) | 97 | 11 |
Bazot [19] | 68% (63/92) | 94 (88,100) | 100 (100,100) | ∞ | 0.06 (0.02, 0.2) | >99 | 11 |
Trans-rectal ultrasound | |||||||
Chapron [13] | 42% (34/81) | 97 (91,100) | 89 (81,98) | 9.1 (4.0,20.9) | 0.03 (0.00, 0.2) | 87 | 2 |
Delpy [14] | 40% (12/40) | 92 (76,100) | 67 (45,88) | 2.8 (1.4,5.0) | 0.1 (0.02,0.8) | 65 | 8 |
Bazot [11] | 67% (54/81) | 89 (81,97) | 93 (83,100) | 12.0 (3.2,45.7) | 0.1 (0.06,0.3) | 96 | 20 |
Piketty [18] | 56% (75/134) | 96 (92,100) | 100 (100,100) | ∞ | 0.04 (0.01,0.1) | >99 | 5 |
Bazot [19] | 68% (63.92) | 89 (81,97) | 93 (84,100) | 12.9 (3.4,49.2) | 0.1 (0.06,0.2) | 96 | 20 |
Magnetic Resonance Imaging (MRI) | |||||||
Chapron [13] | 42% (34/81) | 76 (62,91) | 98 (94,100) | 35.9 (5.1,252.1) | 0.2 (0.1,0.4) | 98 | 15 |
Abrao [10] | 52% (54/104) | 83 (73,93) | 98 (94,100) | 41.7 (6.0,291.1) | 0.2 (0.09, 0.3) | 98 | 16 |
Chamie [12] | 54% (50/92) | 86 (76,96) | 93 (85,100) | 12.0 (4.0,36.0) | 0.2 (0.08, 0.3) | 93 | 15 |
Bazot [19] | 68% (63.92) | 87 (79,96) | 93 (84,100) | 12.7 (3.3,48.4) | 0,1 (0.07,0.3) | 96 | 23 |